APG-157 for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 5 Apr 2022: Trial registered, NCT05312710
  2. 22 Apr 2022: Trial started, NCT05312710

The trials

NCT05312710: Safety and Efficacy of APG-157 in Head and Neck Cancer

State
Under way
Phase
Phase 2
People
24 planned
Started
22 Apr 2022
Primary completion
Dec 2026
Arms
APG-157
Results
None posted
  1. 5 Apr 2022: Trial registered
  2. 22 Apr 2022: Trial started

NCT07667296: APG-157 in Locally Advanced Head and Neck Squamous Cell Carcinoma

State
Not started
Phase
Phase 3
People
826 planned
Started
Jul 2026
Primary completion
Dec 2031
Arms
Cohort A - APG-157, Cohort B - APG-157
Results
None posted
  1. 25 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.